The earnings call highlighted Arcus Biosciences' strong financial position and strategic focus on the casdatifan program, supported by significant investor and investigator enthusiasm. However, there were challenges related to pipeline prioritization and a decline in quarterly revenue.

Company Guidance

In the Arcus Biosciences First Quarter 2025 Earnings Call, the company provided guidance on several key metrics and strategic focuses. The cash runway is bolstered by $1 billion in cash and investments, ensuring funding through pivotal readouts for their late-stage programs, such as casdatifan (cas), domvanalimab (dom), and quemli. The projected 2025 revenue is expected to be between $75 million and $90 million, primarily driven by collaborations with Gilead. The company emphasized the advancement of cas, particularly through the PEAK-1 Phase 3 trial, expected to enroll 700 patients quickly due to investigator enthusiasm and strategic site transitions. Additionally, the company highlighted upcoming data presentations, including cas plus cabo data at ASCO, and their collaboration with AstraZeneca to develop TKI-free regimens in earlier RCC treatment lines. The R&D expenses for the first quarter were $122 million, with a peak in development expenses anticipated for 2025, and a decline expected in 2026 and 2027. The company is also focusing on prioritizing pipeline investments and leveraging strategic collaborations.

Strong Financial Position and Capital Strategy

Arcus Biosciences reported a strong cash position with $1 billion in cash and investments. The company completed a $150 million equity financing in February 2025, ensuring sufficient funding for operations through pivotal readouts for key programs.

Casdatifan Program Advancements

Arcus remains focused on the casdatifan program, with multiple cohorts and combination studies ongoing. The program's data has been selected for oral presentation at ASCO, highlighting its importance and potential in RCC treatment.

Positive Enrollment and Investigator Enthusiasm

The Phase 3 PRISM-1 trial in pancreatic cancer is enrolling rapidly, expected to complete enrollment by the end of 2025. Investigator enthusiasm for the PEAK-1 study is high, supported by prior monotherapy cohort data.

Strategic Collaborations

Arcus is collaborating with AstraZeneca to combine casdatifan with AstraZeneca's anti-PD-1 anti-CTLA-4 bispecific antibody, volrustomig, for a TKI-free treatment option in first-line RCC, enhancing strategic development capabilities.

Arcus Biosciences (RCUS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RCUS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-1.28 / -	-1	―	―	―
Aug 06, 2025	2025 (Q2)	-1.13 / 0.00	-1.02	―		―
May 06, 2025	2025 (Q1)	-1.03 / -1.14	-0.05	-2180.00% (-1.09)
Feb 25, 2025	2024 (Q4)	-1.25 / -1.03	-1.08	4.63% (+0.05)		―
Nov 06, 2024	2024 (Q3)	-1.06 / -1.00	-0.94	-6.38% (-0.06)
Aug 08, 2024	2024 (Q2)	-1.11 / -1.02	-1.04	1.92% (+0.02)
May 08, 2024	2024 (Q1)	-1.01 / -0.05	-1.09	95.41% (+1.04)
Feb 21, 2024	2023 (Q4)	-1.02 / -1.08	-0.93	-16.13% (-0.15)	―
Nov 07, 2023	2023 (Q3)	-1.13 / -0.94	-0.9	-4.44% (-0.04)
Aug 07, 2023	2023 (Q2)	-1.10 / -1.04	-0.93	-11.83% (-0.11)		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RCUS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$9.49	$9.28	-2.21%
May 06, 2025	$8.12	$8.01	-1.35%
Feb 25, 2025	$10.24	$10.14	-0.98%
Nov 06, 2024	$15.73	$16.46	+4.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Arcus Biosciences Inc (RCUS) report earnings?

Arcus Biosciences Inc (RCUS) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is Arcus Biosciences Inc (RCUS) earnings time?

Arcus Biosciences Inc (RCUS) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RCUS EPS forecast?

RCUS EPS forecast for the fiscal quarter 2025 (Q3) is -1.28.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing